MarketPulse

RGX-111

36 articles
BenzingaBenzinga··Djs Law Group

REGENXBIO Hit With Securities Lawsuit Over RGX-111 Safety Disclosures

RGNX faces class action lawsuit alleging false statements about RGX-111 safety. FDA clinical hold imposed after trial participant developed tumor.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Gene Therapy Stock Faces Class Action as FDA Halts REGENXBIO Trial Over Safety Concerns

REGENXBIO faces class action lawsuit after FDA halted RGX-111 gene therapy trial due to CNS tumor, triggering 18% stock decline.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Investors Face April 14 Deadline in Gene Therapy Securities Lawsuit

REGENXBIO ($RGNX) investors have until April 14, 2026 to join securities class action over allegedly misleading RGX-111 trial statements.
RGNXsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Targets REGENXBIO Over RGX-111 Gene Therapy Disclosures

Investors in $REGENXBIO face class action lawsuit alleging false statements about RGX-111 gene therapy development and clinical trial results spanning 2022-2026.
RGNXsecurities fraudclass action lawsuit
BenzingaBenzinga··The Schall Law Firm

RGNX Securities Fraud Lawsuit Opens for Lead Plaintiffs Over RGX-111 Misstatements

Schall Law Firm seeks lead plaintiffs in class action against REGENXBIO for allegedly concealing negative efficacy and safety data on RGX-111 candidate drug.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Hit With Securities Class Action Over Gene Therapy Trial Disclosures

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy. Lead plaintiff deadline April 14, 2026.
RGNXinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Faces Securities Class Action Over RGX-111 Gene Therapy Claims

Securities lawsuit alleges REGENXBIO made misleading statements about RGX-111 gene therapy. Investors have until April 14, 2026 to file.
RGNXsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

RGNX Hit With Securities Fraud Lawsuit Over Concealed Gene Therapy Safety Data

REGENXBIO faces class action securities fraud lawsuit over allegedly concealed safety data for gene therapy RGX-111, triggered by CNS tumor discovery in clinical trial.
RGNXsecurities fraudclass action lawsuit
BenzingaBenzinga··Djs Law Group

REGENXBIO Faces Class Action Over RGX-111 Safety Disclosures Amid FDA Clinical Hold

REGENXBIO ($RGNX) sued for alleged securities violations involving undisclosed adverse trial data on RGX-111 candidate after FDA clinical hold.
RGNXsecurities fraudclass action lawsuit
BenzingaBenzinga··The Schall Law Firm

REGENXBIO Faces Class Action Over Alleged Fraud in Gene Therapy Trial Disclosures

Schall Law Firm seeks $RGNX investors for securities fraud class action alleging false statements about RGX-111 candidate, following tumor discovery in trial participant.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Faces Securities Lawsuit Over Gene Therapy Trial Disclosures

Rosen Law Firm recruits lead plaintiffs for securities class action against REGENXBIO over alleged false statements regarding RGX-111 gene therapy trial data. Lead plaintiff deadline: April 14, 2026.
RGNXsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Faces Securities Lawsuit Over Gene Therapy Trial Disclosures

Rosen Law Firm recruits investors for securities class action against REGENXBIO over alleged RGX-111 gene therapy misstatements. Lead plaintiff deadline: April 14, 2026.
RGNXsecurities class actionmaterial misstatement
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Faces Securities Class Action Over Gene Therapy Misrepresentations

Securities lawsuit filed against $RGNX alleging misleading statements about RGX-111 gene therapy. Eligible investors must act before April 14, 2026 deadline.
RGNXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Gene Therapy Firm REGENXBIO Faces Class Action Over RGX-111 Misstatements

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy development and clinical trials, covering investors from February 2022 through January 2026.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Faces Securities Class Action Over Alleged Misstatements on Product Safety

Rosen Law Firm files securities class action against REGENXBIO for alleged false statements on product safety and efficacy, with April 14, 2026 lead plaintiff deadline.
RGNXEOSESLNOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Gene Therapy Setback: REGENXBIO Faces Class Action Over RGX-111 Misstatements

Class action lawsuit filed against $REGENXBIO alleging false statements on RGX-111 gene therapy. Covers investors from February 2022 to January 2026.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Faces Securities Class Action Over Gene Therapy Misstatements

Securities lawsuit filed against $RGNX for allegedly misleading investors about RGX-111 gene therapy efficacy and safety. Lead plaintiff deadline April 14, 2026.
RGNXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

REGENXBIO Hit With Securities Lawsuit Over Gene Therapy Claims

REGENXBIO faces securities lawsuit over alleged misleading RGX-111 gene therapy statements. Lead plaintiff deadline is April 14, 2026.
RGNXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Gene Therapy Giant REGENXBIO Faces Class Action Over RGX-111 Misstatements

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy. Covers investors from Feb 2022 to Jan 2026; lead plaintiff deadline April 14.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

RegenxBio Faces Securities Lawsuit Over Gene Therapy Claims

RegenxBio faces securities class action alleging misleading RGX-111 gene therapy claims; investors have until April 14, 2026 to file.
RGNXsecurities class actionmisleading statements